Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Study protocol for a duration-randomized clinical trial to determine the optimal length of treatment for multidrug-resistant tuberculosis with a 5-drug regimen: The DRAMATIC trial

Contemporary Clinical Trials(2025)10.1016/j.cct.2025.107875Source: DataRank Database

Study protocol for a duration-randomized clinical trial to determine the optimal length of treatment for multidrug-resistant tuberculosis with a 5-drug regimen: The DRAMATIC trial is a research paper published in Contemporary Clinical Trials (2025). On theSindex it has a DataRank of 0.104. It has been cited 1 time, with 1 citing works in its 1-hop citation network.

N/A

0.104DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access1 citations · 1 citing works in its network

Download PDF

Cite:

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT03828201

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)OA: greenTopics (24)IDs (PubMed, PMC)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.104

From this paper's citation signal

Citation Network Contribution

From 0 citing papers with measurable signal

This paper's DataRank is currently driven only by its base citation score. None of the citing papers had measurable citation signal.

Learn more about DataRank methodology →

Authors (21)

Lelia H. Chaisson ORCID,Zana Wangari Kiragu ORCID,Praewpannarai Buddadhumaruk ORCID,Ariana Austin ORCID,Yilan Gao

Live enrichment

PubMed:40064371 PMC:PMC12083089

National Institutes of Health National Institute of Allergy and Infectious Diseases

Grant: U01 AI152980

National Institutes of Health

Pfizer

greenLicense: http://creativecommons.org/licenses/by-nc/4.0/

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12083089/

publisherhttps://api.elsevier.com/content/article/PII:S1551714425000692?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1551714425000692?httpAccept=text/plain

MeSH Terms

HumansTuberculosis, Multidrug-ResistantNitroimidazolesOxazolesPyrazinamideClofazimineAntitubercular AgentsTreatment OutcomeDrug Therapy, CombinationDrug Administration ScheduleMulticenter Studies as TopicRandomized Controlled Trials as TopicClinical Trials, Phase II as TopicLevofloxacinDiarylquinolinesLinezolid

Keywords

LevofloxacinClinical TrialLinezolidClofazimineMultidrug-resistant TuberculosisBedaquilineDelamanidDuration Randomization